文献速递血管炎

阿伐可泮治疗ANCA相关血管炎的真实世界疗效与安全性:回顾性对照研究

Real-world efficacy and safety of avacopan in ANCA-associated vasculitis: a retrospective comparative study.
PubMed 文献 · RMD Open · 2026-07-15

该单中心回顾性研究纳入35例新发或复发ANCA相关血管炎患者,接受阿伐可泮联合标准诱导治疗,与70例匹配对照比较。6个月缓解率相似,12个月阿伐可泮组缓解率有升高趋势但未达统计学显著;复发率显著降低,激素减量更快、累积剂量更低,肾功能改善更明显。

要点

  • 阿伐可泮组12个月复发率显著低于对照组(16% vs 51%,p=0.003)。
  • 阿伐可泮加速激素减至≤5 mg/天(102 vs 164天,p<0.001)并降低累积剂量。
  • 阿伐可泮组1年eGFR改善更明显(+18 vs +7 mL/min),但26%因不良事件停药。

核心结论

  • 真实世界中阿伐可泮联合标准诱导治疗有效且安全性可接受,具有激素节约、促进肾功能恢复和降低复发率的作用。

研究设计与样本

  • 单中心回顾性对照研究,纳入35例新发或复发AAV患者接受阿伐可泮联合利妥昔单抗、环磷酰胺或两者联合诱导,与70例匹配对照比较。

主要发现

  • 6个月缓解率相似(69% vs 68%),12个月阿伐可泮组有升高趋势(86% vs 68%,p=0.11)。
  • 阿伐可泮组复发率更低(16% vs 51%,p=0.003),包括停药后复发。
  • 阿伐可泮组激素减至≤5 mg/天更快(102 vs 164天,p<0.001),累积剂量更低(3266 vs 4288 mg,p=0.008)。
  • 1年后eGFR改善更明显(+18 vs +7 mL/min)。
  • 9例(26%)因不良事件停用阿伐可泮。

关键数值与推荐

  • 主要终点为6个月和12个月缓解,定义为BVAS=0且泼尼松龙≤5 mg/天。
  • 阿伐可泮组基线中位eGFR较低(24 vs 49 mL/min)。
  • 诱导治疗包括利妥昔单抗(28%)、环磷酰胺(11%)或联合治疗(61%)。

临床怎么用

  • 对于重症AAV患者,阿伐可泮联合标准诱导可考虑用于加速激素减量和降低复发风险。
  • 使用阿伐可泮期间需监测不良事件,因部分患者可能因不良事件停药。

局限性

  • 单中心回顾性设计,样本量较小,长期获益需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Avacopan, an oral C5a receptor antagonist, is approved for treatment of severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in combination with rituximab or cyclophosphamide. This study evaluated its real-world efficacy, safety and glucocorticoid-sparing effects. METHODS: This retrospective single-centre study included 35 patients with new-onset or relapsing AAV treated with avacopan plus standard induction therapy (rituximab, cyclophosphamide or both). Outcomes were compared with 70 matched controls receiving standard therapy. Primary endpoints were remission (Birmingham Vasculitis Activity Score (BVAS)=0, prednisolone ≤5 mg/day) at 6 and 12 months. Secondary endpoints included relapse, renal function, glucocorticoid exposure and adverse events. RESULTS: Baseline characteristics were generally comparable, although median estimated glomerular filtration rate (eGFR) was lower in the avacopan group (24 vs 49 mL/min). Induction therapy included rituximab (28%), cyclophosphamide (11%) or combination therapy (61%), reflecting severe disease. Remission rates were similar at 6 months (69% vs 68%) but tended to be higher with avacopan at 12 months (86% vs 68%; p=0.11). Relapses occurred less frequently with avacopan (16% vs 51%, p=0.003), including after treatment discontinuation. Avacopan was associated with accelerated glucocorticoid tapering (≤5 mg/day; 102 vs 164 days, p<0.001), lower cumulative doses (3266 vs 4288 mg, p=0.008) and greater renal function improvement (ΔeGFR+18 vs +7 mL/min after 1 year). Nine patients (26%) discontinued avacopan due to adverse events. CONCLUSION: In a real-world practice, avacopan was effective with an acceptable safety profile, enabling steroid sparing, improved renal recovery and reduced relapse rates, including in patients receiving combined induction therapy. Benefits persisted beyond 12 months, but prospective confirmation of these presumed long-term benefits is needed.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Thiele F, Schneider J, Prager E, et al. Real-world efficacy and safety of avacopan in ANCA-associated vasculitis: a retrospective comparative study. RMD Open. 2026. PMID: 42457217. doi:10.1136/rmdopen-2026-006792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。